| Item Type | Name |
|
Concept
|
Piperidines
|
|
Academic Article
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
|
|
Academic Article
|
Three-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
|
|
Academic Article
|
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
|
Academic Article
|
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
|
|
Academic Article
|
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
|
|
Academic Article
|
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
|
|
Academic Article
|
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
|
|
Academic Article
|
Ibrutinib: a paradigm shift in management of CLL.
|
|
Academic Article
|
Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
|
Academic Article
|
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
|
|
Academic Article
|
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
|
|
Academic Article
|
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
|
|
Academic Article
|
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
|
|
Academic Article
|
The importance of the tissue microenvironment in hairy cell leukemia.
|
|
Academic Article
|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
|
|
Academic Article
|
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
|
|
Academic Article
|
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
|
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
|
|
Academic Article
|
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
|
|
Academic Article
|
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
|
|
Academic Article
|
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.
|
|
Academic Article
|
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
|
|
Academic Article
|
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
|
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
|
Academic Article
|
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
|
|
Academic Article
|
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
|
|
Academic Article
|
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
|
|
Academic Article
|
Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
|
|
Academic Article
|
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
|
|
Academic Article
|
Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
|
|
Academic Article
|
New pieces in the BTKi resistance puzzle.
|
|
Academic Article
|
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
|
|
Academic Article
|
Safety Analysis of Four Randomized Controlled?Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
|
|
Academic Article
|
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na?ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
|
|
Academic Article
|
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
|
|
Academic Article
|
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
|
|
Academic Article
|
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
|
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
|
Academic Article
|
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
|
|
Academic Article
|
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
|
|
Academic Article
|
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
|
|
Academic Article
|
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib.
|
|
Academic Article
|
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
|
|
Academic Article
|
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
|
|
Academic Article
|
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
|
|
Academic Article
|
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
|
Academic Article
|
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
|
Academic Article
|
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
|
|
Academic Article
|
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
|
|
Academic Article
|
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
|
|
Academic Article
|
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
|
|
Academic Article
|
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
|
|
Academic Article
|
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
|
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
|
Academic Article
|
Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations.
|
|
Academic Article
|
Zanubrutinib for treatment-na?ve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
|
|
Academic Article
|
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
|
|
Academic Article
|
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
|